Endo Announces Master Settlement Agreement Allowing for Resolution of Known Testosterone Replacement Therapy Product Liability Claims and Entry of Significant Case Management Order
"We are very pleased with today's announcement. We believe the master settlement agreement allowing for resolution of all known testosterone replacement therapy product liability claims against
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" including, but not limited to, the statements by Mr. Maletta, as well as Endo's expected, estimated or anticipated future results. Because forecasts are inherently estimates that cannot be made with precision, Endo's performance at times differs materially from its estimates and targets, and Endo often does not know what the actual results will be until after the end of the applicable reporting period. Therefore, Endo will not report or comment on its progress during a current quarter except through public announcement. Any statement made by others with respect to progress during a current quarter cannot be attributed to Endo. All forward-looking statements in this press release reflect Endo's current analysis of existing trends and information and represent Endo's judgment only as of the date of this press release. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Endo's expectations and projections. Risks and uncertainties include, among other things, general industry and market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes, including regulatory decisions, product recalls, withdrawals and other unusual items; challenges related to product marketing, such as the unpredictability of market acceptance for new products and/or the acceptance of new indications for such products; inconsistency of treatment results among patients; potential difficulties in manufacturing; the outcome of litigation, settlement discussions or other adverse proceedings; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations.
View original content:http://www.prnewswire.com/news-releases/endo-announces-master-settlement-agreement-allowing-for-resolution-of-known-testosterone-replacement-therapy-product-liability-claims-and-entry-of-significant-case-management-order-300664310.html
Endo International plc: Media: Heather Zoumas-Lubeski, (484) 216-6829, or Investors: Nina Goworek (484) 216-6657